Biogen Inc

BIIB.O

Official Data Partner

Latest Trade: trading lower283.63USD
Change; -3.89; 1.35%Negative

As of Feb 4 2023. Values delayed up to 15 minutes

Day Range: 282.52 - 291.10
52-Week Range: 187.16 - 311.88

Previous Close: 287.52
Open: 288.57
Volume: 789,153.00
3 Month Average Trading Volume: 24.54
Shares Out (Mil): 144.00
Market Cap: 41,403.29
Forward P/E: 16.80
Dividend Yield: 0.00

Key Statistics

2.17647059 mean rating - 34 analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): 14.65
Price To Sales (TTM): 4.00
Price To Book (Quarterly): 3.24
Price To Cash Flow (Per Share TTM): 14.25
Total Debt/Total Equity (Quarterly): 49.15
Long Term Debt/Equity (Quarterly): 49.15
Return On Investment (TTM): 11.83
Return On Equity (TTM): 9.75

2021 (millions USD)

About Biogen Inc (BIIB.O)

Company Information

Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Address

225 Binney Street
CAMBRIDGE, MA
02142
United States

Contact Information

+1 (781) 4642000

https://www.biogen.com/

Industry

Biotechnology & Drugs

Executive Leadership

Stelios B. Papadopoulos: Independent Chairman of the Board
Christopher A. Viehbacher: President, Chief Executive Officer, Director
Michael R. McDonnell: Chief Financial Officer, Executive Vice President
Ginger Gregory: Chief Human Resource Officer, Executive Vice President
Susan H. Alexander: Executive Vice President, Chief Legal Officer and Secretary
Alphonse Galdes: Executive Vice President, Pharmaceutical Operations and Technology
Rachid Izzar: Executive Vice President, Head of Alzheimers Disease and Dementia Business Unit
Priya Singhal: Executive Vice President - Head of Development
Robin C. Kramer: Senior Vice President, Chief Accounting Officer
Alexander J. Denner: Independent Director
Caroline D. Dorsa: Independent Director
Maria C. Freire: Independent Director
William A. Hawkins: Independent Director
William D. Jones: Independent Director
Jesus B. Mantas: Independent Director
Richard C. Mulligan: Independent Director
Eric K. Rowinsky: Independent Director
Stephen A. Sherwin: Independent Director